11/20
10:24 am
vir
Vir Biotechnology, Inc. (NASDAQ: VIR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $110.00 price target on the stock.
Low
Report
Vir Biotechnology, Inc. (NASDAQ: VIR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $110.00 price target on the stock.
11/20
08:07 am
vir
Vir Biotechnology, Inc. (NASDAQ: VIR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $19.00 price target on the stock.
Medium
Report
Vir Biotechnology, Inc. (NASDAQ: VIR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $19.00 price target on the stock.
11/18
09:19 pm
vir
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program [Yahoo! Finance]
Medium
Report
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program [Yahoo! Finance]
11/18
09:15 pm
vir
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
Medium
Report
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
11/18
04:11 pm
vir
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency [Yahoo! Finance]
Low
Report
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency [Yahoo! Finance]
11/18
04:05 pm
vir
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency
Low
Report
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency
11/15
01:44 pm
vir
What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? [Yahoo! Finance]
Low
Report
What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? [Yahoo! Finance]
11/15
11:04 am
vir
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting [Yahoo! Finance]
Low
Report
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting [Yahoo! Finance]
11/15
11:00 am
vir
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting
Low
Report
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting
11/4
08:19 am
vir
Vir Biotechnology, Inc. (NASDAQ: VIR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $110.00 price target on the stock.
Low
Report
Vir Biotechnology, Inc. (NASDAQ: VIR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $110.00 price target on the stock.
11/4
08:19 am
vir
Vir Biotechnology, Inc. (NASDAQ: VIR) had its price target lowered by analysts at Barclays PLC from $28.00 to $26.00. They now have an "overweight" rating on the stock.
Low
Report
Vir Biotechnology, Inc. (NASDAQ: VIR) had its price target lowered by analysts at Barclays PLC from $28.00 to $26.00. They now have an "overweight" rating on the stock.
11/4
05:50 am
vir
Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results [Yahoo! Finance]
Low
Report
Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results [Yahoo! Finance]
11/2
11:11 am
vir
Vir Biotechnology Third Quarter 2024 Earnings: Misses Expectations [Yahoo! Finance]
Low
Report
Vir Biotechnology Third Quarter 2024 Earnings: Misses Expectations [Yahoo! Finance]
11/1
10:20 am
vir
Vir Biotechnology (NASDAQ:VIR) shareholders have endured a 76% loss from investing in the stock three years ago [Yahoo! Finance]
Medium
Report
Vir Biotechnology (NASDAQ:VIR) shareholders have endured a 76% loss from investing in the stock three years ago [Yahoo! Finance]
11/1
08:15 am
vir
Vir Biotechnology, Inc. (NASDAQ: VIR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $19.00 price target on the stock.
High
Report
Vir Biotechnology, Inc. (NASDAQ: VIR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $19.00 price target on the stock.
10/31
04:05 pm
vir
Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
High
Report
Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
10/17
04:43 pm
vir
Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024 [Yahoo! Finance]
Low
Report
Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024 [Yahoo! Finance]
10/17
04:30 pm
vir
Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024
Low
Report
Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024
10/15
08:17 am
vir
Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD's The Liver Meeting® 2024 [Yahoo! Finance]
Low
Report
Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD's The Liver Meeting® 2024 [Yahoo! Finance]
10/15
08:16 am
vir
Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting® 2024
Low
Report
Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting® 2024
10/5
10:31 am
vir
Vir Biotechnology, Inc. (NASDAQ:VIR) is largely controlled by institutional shareholders who own 53% of the company [Yahoo! Finance]
Medium
Report
Vir Biotechnology, Inc. (NASDAQ:VIR) is largely controlled by institutional shareholders who own 53% of the company [Yahoo! Finance]
10/3
04:00 pm
vir
Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
Medium
Report
Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
9/10
08:05 am
vir
Vir Biotechnology Appoints Jason O’Byrne as Chief Financial Officer
Low
Report
Vir Biotechnology Appoints Jason O’Byrne as Chief Financial Officer
9/9
04:05 pm
vir
Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers
Low
Report
Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers